The Latest Breaking News from Eczema

Australia is often called the allergy capital of the world. Allergic diseases – such as allergic asthma, hay fever, eczema and food allergies – affect almost one in five people. And this figure is expected to rise in the years to come.

Arcutis Biotherapeutics has a lofty goal for 2025 — and it could help Arcutis stock continue a massive run that helped shares quadruple last year.

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval for a new eczema drug called Ebglyss. As the company expands its reach in the diabetes, obesity, and eczema markets, is it a must-have in your healthcare portfolio? Read on to…

Results of study could have ‘hugely significant impact’ and halve allergy rates

Got a beauty dilemma? Our expert is here to offer advice. This week, Aneesah wants to know how to deal with eczema-prone skin

Scarlett Mitchell's battle with eczema highlights the challenges children and their caregivers face, sparking awareness campaign.‌

The new injectable drug, Lebrikizumab, branded as Ebglyss, is approved for treating atopic dermatitis in adults and children aged 12 and older who weigh at least 88 pounds.

The skin is the largest organ of the human body. Not only does it act as the first line of defence against external stressors such as environmental toxins, pathogens and pollutants, our skin can also reveal much about our internal health.

Steroid-free options for soothing, anti-itch care